New Zealand markets close in 25 minutes
  • NZX 50

    11,017.04
    -183.00 (-1.63%)
     
  • NZD/USD

    0.5719
    -0.0011 (-0.20%)
     
  • NZD/EUR

    0.5832
    -0.0001 (-0.01%)
     
  • ALL ORDS

    6,707.80
    -52.80 (-0.78%)
     
  • ASX 200

    6,507.70
    -47.30 (-0.72%)
     
  • OIL

    81.15
    -0.08 (-0.10%)
     
  • GOLD

    1,670.60
    +2.00 (+0.12%)
     
  • NASDAQ

    11,164.78
    -329.05 (-2.86%)
     
  • FTSE

    6,881.59
    -123.80 (-1.77%)
     
  • Dow Jones

    29,225.61
    -458.13 (-1.54%)
     
  • DAX

    11,975.55
    -207.73 (-1.71%)
     
  • Hang Seng

    17,155.07
    -10.80 (-0.06%)
     
  • NIKKEI 225

    25,979.75
    -442.30 (-1.67%)
     
  • NZD/JPY

    82.7610
    +0.0140 (+0.02%)
     

X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference

·2-min read
X4 Pharmaceuticals
X4 Pharmaceuticals

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

Details are as follows:

Conference: Canaccord Genuity 42nd Annual Growth Conference  
Format: Corporate Overview
Date: Thursday, August 11, 2022
Time: 3:30 PM ET
Corporate Overview Webcast Link

A live webcast of the presentation will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com. After the live webcast, this event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system. Our lead clinical candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor’s ability to antagonize CXCR4 and improve the healthy maturation and mobilization of white blood cells, we believe that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including a range of chronic neutropenic disorders and certain types of cancer. The efficacy and safety of mavorixafor are being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. We are also studying mavorixafor in two Phase 1b clinical trials – one as a monotherapy in patients with chronic neutropenic disorders including congenital, idiopathic, and cyclic neutropenia, and one in combination with ibrutinib in patients with Waldenström’s macroglobulinemia (WM), a rare B-cell lymphoma. Further clinical development of mavorixafor in WM will now be subject to completing a strategic partnership as we focus our resources on advancing mavorixafor for the benefit of patients with chronic neutropenic disorders. We continue to leverage our insights into CXCR4 biology at our corporate headquarters in Boston, Massachusetts and at our research facility in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Contacts:
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina, Ph.D. (media)
Account Supervisor, LifeSci Communications
mroucomolina@lifescicomms.com